OBJECTIVE: To assess whether the use of CBDbased drugs leads to better control of
epileptic seizures in patients with difficulttocontrol epilepsy. METHOD: this is a clinical
cohort study, based on the analysis of 34 medical records for the selection of patients
undergoing treatment for epilepsy who are refractory to standard antiepileptic therapy and vagal
nerve stimulation (VNS) therapy and who are using derivatives cannabinoids, being followed
up at the Ophir Loyola Hospital and the Institute of Functional Neurosurgery, Epilepsy and
Medicinal Cannabis Dr. Francinaldo Gomes, from January 2021 to July 2022. RESULTS: Of
the 34 medical records analyzed, 22 met the inclusion criteria of the study, so that, after 3
months of treatment with cannabidiol, there was a reduction in the absolute frequency of
seizures from 14.43 seizures per month to 12.6, and with 6 months of treatment, reduction to
8.36, and with 9 months of treatment, reduction to 3.27 seizures per month, and finally, with 12
months of treatment, reduction to an average of 2.84 seizures per month , thus showing an
average reduction of 80.31%. CONCLUSION: This analysis allowed us to reaffirm, in
accordance with the international literature, the benefits of cannabidiol as an adjuvant to
conventional antiepileptic therapy, and may serve as subsidiary for actions aimed at increasing
access to cannabidiolbased formulations in the treatment of epilepsy.
|
